Inve US ▾
CTCTKB

Cytek Biosciences (CTKB) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

Cytek Biosciences Q2 FY26 — Strong US & China Growth, New Product Launches

Cytek Biosciences reported solid Q2 FY26 results, driven by robust revenue growth in the US and China, alongside the successful launch of two new high-end flow cytometry instruments. The company is undergoing a strategic reorganization into three customer-aligned business units to enhance market penetration and optimize resource allocation. While facing headwinds in EMEA and parts of APAC, management remains focused on expanding its recurring revenue base and leveraging technological leadership for sustainable long-term growth.

Highlights

5

  • Second quarter revenue increased 6% year-over-year to $48.1 million.

  • US revenue grew 18% year-over-year to $28.2 million, driven by academic and government sectors.

  • China delivered strong double-digit growth in revenue.

  • High-end FSP instrument portfolio grew 11% year-over-year.

  • Recurring revenue (reagents and service) increased 8% year-over-year to $18.5 million, representing 35% of LTM revenue.

Concerns

5

  • EMEA revenue was down approximately 8% year-over-year to $11.3 million due to budgetary pressures.

  • Academic and government revenue declined approximately 12% year-over-year to $19.1 million, primarily due to weakness in EMEA and other APAC.

  • GAAP net loss increased to $12.2 million from $5.6 million in Q2 2025.

  • Adjusted EBITDA was a loss of $1.5 million in Q2 2026, compared to a positive $1.3 million in Q2 2025.

  • General and administrative expenses increased 24% to $16.8 million, primarily due to higher legal expenses and severance costs.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Revenue
$207 million to $212 million
high materiality
High
Full-year 2026 Adjusted EBITDA
around break-even
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
United States
Strong trend from Q1, reflecting impressive growth in instrument revenue in the academic and government sector and in service business. Biopharma in US was relatively flat in Q2, but up 20% in H1.
$28.2 million18%——
EMEA
Reflecting a continuation of budgetary pressures arising from regional geopolitical dynamics. EMEA instrument revenue declined 10% year-over-year.
$11.3 million-8%——
APAC (including China)
China delivered strong double-digit growth against a modest year-on-year comp, which was offset by softness in other parts of the region. Product revenue in APAC excluding China was lower due to normal fluctuations after a strong Q1.
$7.9 million———

Product announcements

ProductTypeDetails
Cytek Borealislaunch
Aurora EVO instrument configurationexpansion

Risks & headwinds

Geopolitical dynamics and budgetary pressures in EMEA Q2 FY26, continuing trend

EMEA revenue down approximately 8% year-over-year to $11.3 million; EMEA instrument revenue declined 10% year-over-year.

Mitigation:Focus on new product launches and sales/marketing investments in other regions; strategic reorganization to better align resources.

Weakness in academic and government sectors in EMEA and other APAC Q2 FY26

Academic and government revenue down approximately 12% year-over-year to $19.1 million.

Mitigation:Strong US academic and government growth partially offset this weakness; new product launches expected to attract interest globally.

Increased legal expenses and severance costs Q2 FY26

General and administrative expenses up $3.3 million or 24% to $16.8 million.

Mitigation:Operating expense growth expected to moderate in the second half of the year.

Foreign exchange losses and non-recurring write-off Q2 FY26

Lower net other income by $4.5 million, including $0.7 million FX losses and $1.6 million write-off.

Mitigation:Adjusted EBITDA excludes foreign exchange impacts and non-recurring write-offs; expected to improve in H2.

What to watch in Q3 FY26

EMEA revenue trend

next quarter
Current Down 8% YoY
Target Stabilization or improvement

Why it matters

EMEA is a significant region experiencing budgetary pressures; its recovery is key to overall international growth.

In a year, second world revenue was $11.3 million, down approximately 8% year over year, reflecting a continuation of the budgetary pressures arising from regional geopolitical dynamics.

Find out whether CTKB delivers this. Inve re-checks your case every morning.

Q&A highlights

With improving biotech funding, will growth across end markets equilibrate? What levers are available to capitalize on recovery in US vs. other geographies?

Management noted strong US academic/government growth, while US biopharma was flat in Q2 but up 20% in H1. EMEA and other APAC faced budgetary pressures. New products (Borealis, Aurora Evo automation) and continued investment in sales/marketing are key levers. Cytek's technology leadership is a global advantage.

“We have significant new products that we talked about, the Borealis, the Aurora Evo automation, with enhanced automation, which are attracting very strong interest from customers. We continue to invest in our sales and marketing infrastructure and And our brand is very strong and we And it represents really the leading technology in the space.”

asked by Brendan Smith · answered by William McCombe

2 min read 5 chapters

Detailed narrative

Strategic Reorganization for Enhanced Customer Focus

Cytek is implementing a strategic reorganization in Q3 2026, transitioning to three distinct customer-aligned business units: Solutions and Clinical, Research Technology, and Service. This restructuring aims to better align resources with different customer segments, particularly to improve market penetration in mid- and low-end instruments and reagents. Management expects this initiative to enhance top-line growth and market penetration, though significant benefits are anticipated to materialize over time.

New Product Innovation Driving Growth

The company launched two significant new products: the Borealis, the industry's first 60-color, 7-laser full-spectrum flow cytometer, and the Aurora EVO instrument configuration with expanded automation capabilities. The Borealis significantly expands cellular biomarker analysis and offers increased efficiency, while the Aurora EVO enhances integration into automated lab environments, particularly for biopharma and CROs. These launches underscore Cytek's commitment to technological leadership and are attracting strong customer interest.

Geographic Performance and Market Dynamics

Q2 FY26 saw strong performance in the US, with 18% year-over-year revenue growth, primarily from academic and government customers. China also delivered strong double-digit growth. However, EMEA revenue declined 8% due to regional geopolitical dynamics and budgetary pressures, and other APAC regions experienced softness. Management noted that the strong US academic and government growth offset weakness in these sectors in EMEA and other APAC.

Recurring Revenue Base Strengthening

Cytek's recurring revenue, comprising reagents and service, grew 8% year-over-year to $18.5 million, now representing 35% of the last 12 months' revenue, up from 32% in the prior year. Service revenue alone grew 10% year-over-year, driven by an expanding install base and high instrument utilization. The company expects recurring revenue to continue increasing as a percentage of total revenue, supported by the growing install base and active instrument use.

Cytacloud User Growth and Ecosystem Engagement

The Cytacloud platform continues to play a critical role in optimizing experimental workflows, with users surpassing 28,000 as of June 30, 2026, a 15% increase since the start of the year. This growth reinforces the strength of Cytek's integrated ecosystem and drives deeper customer engagement, which is considered an important factor in driving growth in the reagents and service businesses.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.